Evaluation of efficacy and safety of naftifine versus terbinafine in the treatment of dermatophytosis: a randomized, open label, parallel group, active controlled, multi-centre study.

Sun Pharmaceutical Industries Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Pregnant or lactating women and women of childbearing potential who are not on an acceptable birth control methods.
•2.Patients with any systemic condition predisposing them to fungal infection or with any skin disease that might interfere with the study.
•3.Patients using topical antifungals, topical corticosteroids, or systemic antibacterials before 14 days of study entry.
•4.Patients using systemic antifungals or corticosteroids before 4 weeks of the study entry.
•5.Patients using other concomitant systemic or topical therapy with antibiotics, antimycotics or corticosteroids.
•6.Patients having hypersensitivity with Naftifine or Terbinafine.
•7.Patients having a serum creatinine of > 1.5 x upper limit of normal.
•8.Patients having history of alcohol, narcotic or drug abuse.
•9.Patients with severe renal and hepatic impairment.
•10.Patients having thyroid stimulating hormone value outside the normal range.

发起方